- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.04. | Flerie AB: Flerie AB (publ) Interim Report January - March 2026 | 87 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 3,670 million (3,947) and net asset value per share was SEK 41.90 (50.56 at 31 March 2025). Change in net asset value per share in the quarter was -3.9 per... ► Artikel lesen | |
| 26.03. | Flerie AB: Bulletin from the Annual General Meeting of Flerie AB (publ) on 26 March 2026 | 295 | GlobeNewswire (Europe) | The Annual General Meeting of Flerie AB (publ) reg. no. 559067-6820 (the "Company") has been held on 26 March 2026 and in particular the following resolutions were made.
Adoption of the annual report... ► Artikel lesen | |
| 20.03. | Flerie AB: The merger between Flerie and Lipum has been completed | 201 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 12.03. | Lipum AB: The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Lipum | 199 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 11.02. | Flerie AB: Flerie's portfolio company Microbiotica reports positive Phase 1b data for MB310 in patients with ulcerative colitis | 220 | GlobeNewswire (Europe) | Flerie AB's (publ) portfolio company Microbiotica has reported positive results from its Phase 1b first-in-human study of MB310 in patients with ulcerative colitis (UC). The positive data support Microbiotica's... ► Artikel lesen | |
| 02.02. | Flerie AB: Flerie's portfolio company Nanologica acquires Syntagon | 477 | GlobeNewswire (Europe) | Flerie AB (publ)'s portfolio company Nanologica has acquired Ardena Södertälje AB ('Syntagon'), a contract manufacturer with 45 employees. The acquisition strengthens Nanologica's production capacity... ► Artikel lesen | |
| 21.01. | Flerie AB: Flerie AB (publ) Year-end report 2025 | 161 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 3,377 million (4,198) and net asset value per share was SEK 43.60 (53.77 at 31 December 2024). Change in net asset value per share in the quarter was -13.8... ► Artikel lesen | |
| 20.01. | Flerie AB: Flerie's portfolio company Chromafora acquires Montrose Environmental Group Denmark | 280 | GlobeNewswire (Europe) | Flerie AB's (publ) portfolio company Chromafora has acquired Montrose Environmental Group Denmark, a Danish specialist in PFAS and provider of technical solutions for contaminated water treatment. The... ► Artikel lesen | |
| FLERIE Aktie jetzt für 0€ handeln | |||||
| 09.01. | Flerie AB: Flerie's portfolio company KAHR Bio presents strong survival data from Phase II trial with DSP107 and secures USD 22 million in equity funding | 223 | GlobeNewswire (Europe) | Flerie AB's (publ) portfolio company KAHR Bio announced a median overall survival of 17.5 months in its Phase II trial with DSP107, combined with the anti-PD-L1 immunotherapy atezolizumab, in patients... ► Artikel lesen | |
| 29.12.25 | Flerie AB: Bulletin from the Extraordinary General Meeting of Flerie AB (publ) on 29 December 2025 at 10:00 CET | 204 | GlobeNewswire (Europe) | The Extraordinary General Meeting of Flerie AB (publ) reg. no. 559067-6820 ("Flerie" or the "Company") has been held on 29 December 2025 at 10:00 CET at which the following resolutions were made.
Resolution... ► Artikel lesen | |
| 11.12.25 | Flerie AB: Flerie receives FDI-approval for the merger with Lipum | 236 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 05.12.25 | Flerie AB: Flerie intends to divest its holdings in the Limited Partnership segment | 197 | GlobeNewswire (Europe) | Flerie AB (publ) intends to divest its entire holdings in the investment funds that constitute the company's Limited Partnership segment. The divestment will be subject to a decision at an extraordinary... ► Artikel lesen | |
| 18.11.25 | Flerie AB: Flerie and Lipum have agreed on a merger plan | 232 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 22.10.25 | Flerie AB: Flerie AB (publ) Interim Report January - September 2025 | 183 | GlobeNewswire (Europe) | The period in brief• Net asset value was SEK 3,918 million (4,262) and net asset value per share was SEK 50.58 (54.59 at 30 September 2024). Change in net asset value per share in the quarter was -4.2... ► Artikel lesen | |
| 23.09.25 | Flerie AB: Flerie's portfolio company Xintela has presented positive 24-month data for its stem cell product XSTEM | 248 | GlobeNewswire (Europe) | Stockholm, Sweden, September 23, 2025. Flerie AB's (publ) portfolio company Xintela has announced that its stem cell product XSTEM continues to demonstrate safety, reduction in knee pain, improved joint... ► Artikel lesen | |
| 19.08.25 | Flerie AB: The merger between Flerie and Toleranzia has been completed | 272 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEELAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 08.08.25 | Toleranzia AB: The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Toleranzia | 306 | GlobeNewswire (Europe) | The Swedish Companies Registration Office (Sw. Bolagsverket) has granted permission to Flerie AB (publ) ("Flerie") to carry out the merger plan concerning the merger between Flerie and Toleranzia AB... ► Artikel lesen | |
| 31.07.25 | Flerie AB: The Board of Directors of Flerie has resolved to redeem all Series C shares within the framework of Flerie's share redemption scheme | 244 | GlobeNewswire (Europe) | At an Extraordinary General Meeting of Flerie AB (publ) ("Flerie" or the "Company") held on 10 June 2024, a resolution was passed to introduce a redemption scheme for the Company's shares. Redemption... ► Artikel lesen | |
| 31.07.25 | Flerie AB: Flerie AB (publ) Interim Report January - June 2025 | 247 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 4,121 million (4,380) and net asset value per share was SEK 52.78 (SEK 56.10 at 30 June 2024). Change in net asset value per share in the quarter was 4.4 per... ► Artikel lesen | |
| 16.07.25 | Flerie AB: Flerie AB's subsidiary Flerie Invest AB announces final outcome of the mandatory cash offer to the shareholders of Nanologica AB (publ) | 758 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO ANY JURISDICTION (INCLUDING WITHOUT LIMITATION AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HAEMATO | 11,400 | +0,88 % | M1 Kliniken schließt Verkauf von Haemato Pharm ab | Die M1 Kliniken AG hat den Verkauf der Haemato Pharm GmbH über ihre Mehrheitsbeteiligung Haemato AG an die Phoenix Group mit Wirkung zum Ablauf des 31. Januar 2026 abgeschlossen. Sämtliche Vollzugsbedingungen... ► Artikel lesen | |
| EYEPOINT | 11,000 | -2,65 % | EyePoint, Inc.: EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 | ||
| PHOTOCURE | 5,890 | -3,12 % | PHOTOCURE: Photocure ASA: Invitation to presentation of first quarter 2026 financial results | ||
| SEAPORT THERAPEUTICS | 19,840 | 0,00 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 28,910 | +19,86 % | Eton Pharmaceuticals relaunches HEMANGEOL (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution | HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 86,91 | -1,18 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| LB PHARMACEUTICALS | 31,355 | -1,12 % | This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | ||
| BIOHAVEN | 9,630 | +0,57 % | Biohaven Ltd.: Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results | Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM)... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,390 | -1,83 % | KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer | ||
| AQUESTIVE THERAPEUTICS | 4,190 | +2,07 % | Vergessene Biotech-Chance: Kann Aquestive Therapeutics vor dem Durchbruch stehen? | Aquestive Therapeutics steht trotz operativer Fortschritte und potenziell wertvoller Pipeline unter massivem Bewertungsdruck. Die Aktie notiert deutlich unter früheren Kursniveaus, während sich fundamentale... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,340 | +4,46 % | Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It's A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning... ► Artikel lesen | |
| SHUTTLE PHARMACEUTICALS | 0,708 | -31,93 % | Shuttle Pharmaceuticals Holdings Inc.: United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation | Gaithersburg, Maryland--(Newsfile Corp. - May 1, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin... ► Artikel lesen | |
| OMNIAB | 1,400 | +0,72 % | OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026 | ||
| MILESTONE PHARMACEUTICALS | 1,870 | +3,89 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST (etripamil) Nasal Spray for the Treatment of PSVT | FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic... ► Artikel lesen | |
| JOURNEY MEDICAL | 5,185 | +0,68 % | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLERIE AB finden Sie auf Wallstreet Online.